Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma

UBONRAT THAMRONGWARANGGOON^{1,2}, SAKKARN SANGKHAMANON³, WUNCHANA SEUBWAI^{2,4},
PAKSIREE SARANARUK¹, UBON CHA'ON¹ and SOPIT WONGKHAM^{1,2}

¹Department of Biochemistry, and Center for Translational Medicine,
Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand;

²Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand;

³Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand;

⁴Department of Forensic Medicine, Faculty of Medicine, Faculty of Medicine,
Khon Kaen University, Khon Kaen, Thailand

Abstract. *Background/Aim:* Glucose transporter 1 (GLUT1) has been demonstrated to be overexpressed in various cancer tissues and play a significant role on growth, metastasis, and apoptosis in cancer cells. This study aimed to reveal the clinical relevance of glucose transporter 1 (GLUT1) in carcinogenesis and progression on liver fluke-associated cholangiocarcinoma (CCA). *Materials and Methods:* Expression of GLUT1 in CCA tissues from patients, as well as from a liver fluke-induced CCA hamster model, was determined using immunohistochemistry. CCA cell lines were transfected with GLUT1 siRNA and the roles of GLUT1 on cell growth as well as migration and invasion were investigated by using a clonogenic assay and Boyden chamber assays, respectively. *Results:* GLUT1 was aberrantly expressed in hyperplastic/dysplastic bile ducts and CCA, but not in the normal bile ducts. High GLUT1 expression was significantly associated with non-papillary type, large tumor size, and short survival of patients. GLUT1 was expressed during cholangio-carcinogenesis and gradually increased with progression of histopathologic bile ducts. Silencing of GLUT1 expression significantly suppressed growth, migration, and invasion of CCA cell lines. *Conclusion:* GLUT1 plays important roles in carcinogenesis and progression of liver fluke-associated CCA. Targeting GLUT1 may be a strategy for treatment of metastasis in liver fluke-associated CCA.

The well-known aerobic glycolysis or Warburg effect (1) is a phenomenon when cancer cells reprogram their glucose metabolism *via* increasing glucose uptake and glycolytic activity even in the presence of oxygen. This event is one of the hallmarks for cancer to maintain energy and contribute the intermediates for *de novo* synthesis of lipids, nucleotides, and amino acid (2).

Cells uptake glucose *via* glucose transporters (GLUTs) that are a key rate-limiting factor in transporting glucose into cells and accelerate glycolysis. At present, there are 14 GLUTs (GLUT1-14 or SLC2A1-14) reported in humans (3). Among these, GLUT1 is reported to be over-expressed in various tumor tissues (4) and related to aggressive phenotypes, *e.g.*, high proliferation rate, metastasis as well as resistances to chemo- and radio-therapy in a range of tumor entities (5, 6). Therefore, targeting GLUTs and pathways related to glucose metabolism has become a novel strategy for cancer therapy.

Cholangiocarcinoma (CCA) is the second most common liver cancer; the incidence and mortality rates of which are increasing globally (7). The incidence of CCA is particularly high in the Northeast of Thailand and countries around the Great Mae-Kong subregions (8). A known risk factor of CCA in this region is the liver fluke (*Opisthorchis viverrini*, Ov) infection that creates a chronic inflammation in the biliary system (8). Lack of early diagnosis and effective treatments for CCA patients, as well as the highly metastatic nature of CCA, result in a poor patient outcome. In addition, CCA has a high recurrence rate even in the operative cases with a low 5-year survival (9). A new strategic approach for a better treatment is therefore, urgently required.

Our previous studies demonstrated that up-regulation of hexokinase 2 (10) and lactate dehydrogenase A (11) were related to poor prognosis of CCA patients. These observations indicated that CCA might have a high glycolytic rate and high glucose uptake implying the high

This article is freely accessible online.

Correspondence to: Sopit Wongkham, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand. Tel: +66 43348386 Fax: +66 43363319 e-mail: sopit@kku.ac.th

Key Words: Glucose transporter 1, cholangiocarcinoma, prognostic marker, poor prognosis, *Opisthorchis viverrini*.

GLUT1 expression in CCA. Significant association of GLUT1 expression with aggressive potential in non-fluke related CCA has been reported by Kubo *et al.* in 2014 (12). As expression profiles, mutations and epigenetic landscapes (13) of fluke-related intrahepatic CCA were different from those of the non-fluke-related intrahepatic CCAs, the involvement of GLUT1 in tumor development and progression of fluke-related CCA remains to be elucidated.

The present study aimed to reveal the involvement of GLUT1 expression in carcinogenesis and progression of liver fluke-associated CCA. Therefore, GLUT1 expression was investigated in CCA tissues from a liver fluke-induced CCA hamster model. Moreover, the effects of GLUT1 knockdown on cell growth, migration, and invasion were investigated in CCA cell lines.

Materials and Methods

Patients. The study protocol was approved by The Khon Kaen University Ethics Committee for Human Research (HE591063). Paraffin-embedded liver tissues from histologically proven CCA patients (n=82) were obtained from the biobank of Cholangiocarcinoma Research Institute, Faculty of Medicine, Khon Kaen University, Thailand. All tissue samples were from Thai CCA patients who lived in the endemic area of Ov infection and had active or history of Ov infection. Informed consent was obtained from each patient.

Tissues from Ov-induced CCA hamsters. The liver sections from Ov-induced CCA hamsters were obtained as previously described (14). Briefly, hamsters were grouped into: non-treated control, Ov infected, *N*-nitroso dimethylamine (NDMA) treated, and Ov + NDMA treated groups (5 animals each). Liver tissues were collected at 1, 3, and 6 months after treatment. The protocols for animal handling and treatment were approved by the Animal Ethics Committee, Khon Kaen University, Thailand (AEMDKKU1/2558).

Cell lines and cell culture. The CCA cell lines, KKKU-100 and KKKU-213A, were established from CCA tissues of Thai patients with Ov eggs were evident in the tumor tissues (15, 16). These two cell lines were obtained from the Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan. Cells were cultured in HAM-F12 media (Gibco/BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco/BRL), at 37°C with 5% CO₂.

GLUT1 expression data from the Gene Expression Profiling Interactive Analysis (GEPIA) dataset. GEPIA (<http://gepia2.cancer-pku.cn/>) is a web server for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects, using a standard processing pipeline (<http://gepia2.cancer-pku.cn/>). The differential expression of GLUT1 in CCA and the normal bile ducts (NBD) were compared using one-way ANOVA (17).

Immunohistochemical analysis. Protein expression of GLUT1 was examined in paraffin embedded tissues from CCA patients and Ov-induced CCA hamsters by immunohistochemistry (IHC), following the standard protocol (18). The sections were incubated with 1:200 anti-

GLUT1 antibody (ab40084, Abcam, Cambridge, UK) at room temperature, overnight and then with peroxidase-conjugated Envision™ secondary antibody (Dako, Carpinteria, CA, USA) for 1 h at room temperature. Positive signal was developed and observed under a light microscope (Axioscope A1, Carl Zeiss, Jena, Germany). The intensity of the signals was scored as 1=weak, 2=moderate, 3=strong and the number of positive cells were graded as 0%=negative, 1-25%=1, 26-50%=2 and 51-75%=3. The expression level of GLUT1 was semi-quantitated according to the IHC scores as intensity × frequency (10) and designated as low and high according to the median.

SDS-PAGE and western blot. NP-40 lysis buffer was used for cell lysis and the Lowry method (19) was performed to determine the concentration of proteins. Proteins were separated and transferred to the Hybond™-P PVDF membrane (GE Healthcare, Buckinghamshire, UK) by wet electro-transferring using the Bolt & Mahoney buffer (20). The membrane was incubated with blocking solution (5% skim milk in PBS with 0.3% Tween-20) and then incubated with the primary antibody, 1:2,000 anti-GLUT1 (ab14683; Abcam) or 1:10,000 anti-actin (A5441; Sigma, St. Louis, MO, USA). Signals were developed with the ECL™ Prime Western Blotting Detection System (GE healthcare). ECL signals were detected with Image Quant LAS 4000 mini-image analyzer and quantitated using Image Quant™ TL analysis software (GE healthcare).

RNA extraction and real-time reverse transcriptase polymerase chain reaction. Total RNA was extracted from CCA cell lines using the trizol reagent (Invitrogen, Carlsbad, CA, USA) and reversed to cDNA using the high capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Vilnius, Lithuania). The PCR was performed in the Light Cycle 480® real-time PCR system (Roche Diagnostics, Mannheim, Germany) using Light Cycle 480® SYBR green I master mix (Roche Diagnostics) and GLUT1 primers: forward: 5'-CTTTGTGGCCTTCTTTGAAGT-3', reverse: 5'-ACACAGTTGCTCCACAT-3'.

RNA silencing. GLUT1 expression in CCA cell lines was suppressed by transient transfection of GLUT1-siRNA using Lipofectamine® 2000 (Invitrogen). The siRNA sequences were as previously described (21). GLUT1-siRNA (50 pmole) was transfected into 8×10⁴ CCA cells in a serum free-HAM-F12 media. Complete media was added after 6 h. Scrambled siRNA (SC) (Qiagen, Hilden, CA) served as a negative control.

Clonogenic assay. CCA cells were treated with siGLUT1 for 48 h and then seeded into a 24-well plate (80 cells/well). The plates were incubated at 37°C in a 5% CO₂ incubator for 7 days with media being replaced on day 4. A cluster of more than 50 cells was counted as 1 colony under the microscope.

Cell migration and invasion assay. Cell migration and invasion assays were performed using 8-μm pore transwell plates (Corning, Lowell, MA, USA). The transwells were pre-coated with 40 μg Matrigel/insert (Corning) for the invasion assay. CCA cells were treated with siGLUT1 for 48 h and viable cells of 5×10⁴ from KKKU-100 and 4×10⁴ from KKKU-213A cells were seeded into the upper chamber. Cells were allowed to move or invade, 16 h for KKKU-100 and 6 h for KKKU-213A. The migrated or invaded cells were fixed and stained with 1:20,000 Hoechst 33342 for 15 min at room temperature (Invitrogen) and counted under a microscope.

Figure 1. GLUT1 is overexpressed in human cholangiocarcinoma (CCA) tissues and correlates with short survival of CCA patients. Comparison of GLUT1 mRNA expressed in CCA tissues from patients and normal bile ducts (NBD) and in the adjacent tissues. Data were analyzed using TCGA data (<http://gepia2.cancer-pku.cn/>) (A). GLUT1 immunohistochemical (IHC) staining in NBD, hyperplasia (HP), dysplasia (DP), papillary type (Pap) and non-papillary type (Non-pap) CCAs (magnification 200 $\times$). scale bar=100 μ m (B). The IHC score of GLUT1 observed in CCA tissues vs. NBD (C). Percent of GLUT1 expression in each histopathological bile duct. Numbers indicate numbers of GLUT1 positive/total number of cases (D). Patients with high GLUT1 expression had shorter survivals than those with low GLUT1 expression (E). Data in (A) and (C) are presented as mean $\pm$ SD, numbers in the parentheses represent numbers of samples, *** p <0.001.

Statistical analysis. The experiments were performed in duplicates or triplicates and repeated three independent times. The data are presented as mean $\pm$ standard deviation (SD). The statistical differences between groups were compared using Pearson chi-square, one-way ANOVA and the Student *t*-test. Survival analysis was performed using Kaplan-Meier method and log-rank test. All *p*-values<0.05 were considered significant. All analyses were performed using SPSS 17.0 software (SPSS, Chicago, IL, USA).

Results

GLUT1 was highly expressed in human CCA tissue and not in normal adjacent tissue. The levels of GLUT1 mRNA in

patient CCA tissues were investigated using the data source from GEPIA. The expression levels of GLUT1 mRNA were significantly higher in CCA tissues (n=36) than the adjacent normal tissues (n=9) (p <0.005; Figure 1A). Protein expression of GLUT1 was also examined in the CCA tissue sections from 82 Thai patients. A positive signal of GLUT1 was observed in both plasma membranes and cytoplasm of hyperplastic/dysplastic (HP/DP) bile ducts and CCA, but not in the NBD in adjacent non-tumor tissues (n=77; Figure 1B). The mean IHC scores of GLUT1 observed in CCA tissues were significantly higher than those of NBD (p <0.005; Figure 1C). Differential expression of GLUT1 was detected

Table I. Univariate analysis demonstrates the association of Glucose transporter 1 (GLUT1) expression and clinicopathologic characteristics of cholangiocarcinoma (CCA) patients.

Variables	GLUT1 expression			p-Value
	n	Low (n)	High (n)	
Age (years)				
<56	39	19	24	0.773
≥56	43	16	23	
Gender				
Female	27	11	16	0.803
Male	55	24	31	
Histological type				
Papillary	27	17	10	0.009
Non papillary	55	18	37	
Tumor size (cm)				
<5	18	12	6	0.030
≥5	64	23	41	
Tumor stage				
I-III	34	15	19	0.825
IV	48	20	28	
Lymph node metastasis				
No	52	22	30	0.928
Yes	30	13	17	

Significant *p*-values are shown in bold.

in pathologic bile ducts. The positive signals of GLUT1 were gradually increased with an increasing degree of bile duct pathology; hyperplasia (21%), dysplasia (34%), papillary type (67%) and non-papillary type CCA (89%) (Figure 1D). These results implied the involvement of GLUT1 in the development and progression of CCA in humans.

High GLUT1 expression is correlated with poor prognosis of CCA patients. To examine the clinical relevance of GLUT1 in CCA, the association of GLUT1 expression with the clinicopathological features of CCA patients was examined. CCA patients were divided according to the median of GLUT1-IHC scores into low (IHC score <4) and high (IHC score ≥4). Univariate analysis indicated that high GLUT1 expression was correlated with non-papillary type CCA and tumor size of larger than 5 cm ($p=0.03$ and $p=0.009$, respectively; Table I). Overall survival analysis using the Kaplan-Meier method showed that CCA patients with high GLUT1 expression had significantly shorter survival than those with low GLUT1 expression ($p=0.024$; Figure 1E). The univariate analysis using the Cox regression model demonstrated that the non-papillary type CCA ($p=0.002$) and high expression of GLUT1 ($p=0.025$) were significantly correlated with poor survival for patients with CCA. Moreover, multivariate analysis indicated that high level of GLUT1 was an independent predictor for poor survival in CCA patients (HR=1.698, $p<0.029$; Table II).

Table II. Multivariate analysis for overall survival using a Cox proportional hazards regression model.

Variables	Multivariate analysis		
	HR	95% CI	p-Value
Age (years)			
<56	1		
≥56	1.017	0.650-1.592	0.940
Gender			
Female	1		
Male	0.868	0.539-1.592	0.561
Tumor size (cm)			
<5	1		
≥5	1.618	0.916-2.859	0.097
Tumor stage			
I-III	1		
IV	1.228	0.650-2.321	0.527
Lymph node metastasis			
No	1		
Yes	0.839	0.520-1.354	0.473
GLUT1 expression			
Low	1		
High	1.698	1.057-2.726	0.029

HR, Hazard ratio; CI, confidence interval. Significant *p*-values are shown in bold.

Up-regulation of GLUT1 is associated with carcinogenesis of CCA. To investigate the association of GLUT1 with carcinogenesis of CCA, GLUT1 expression was evaluated in the liver sections of Ov-induced CCA hamsters collected at 1, 3, and 6 months post-treatment. There were three control groups in this model; the non-treated, Ov infected, and NDMA treated groups. CCA was induced in the Ov + NDMA group. There was no CCA development in the control groups at all treatment periods, whereas CCA was developed in the Ov + NDMA group observed at 3 and 6 month-periods. The IHC results revealed that no GLUT1 signal was observed in the NBD and hepatocytes from all animal groups at every time point (Figure 2A). Most of the hyperproliferative bile ducts from Ov-infected and NDMA treated groups were negative for GLUT1. In contrast, GLUT1 expression was detected in the hyperproliferative bile ducts of the Ov + NDMA treated group as early as 1-month of CCA induction. Membranous staining with moderate to high expression levels of GLUT1 were observed in almost all CCA tissues developed at 3- and 6-months post-treatment (Figure 2A-B). The aberrant expression of GLUT1 in CCA tissues from Ov-induced hamsters indicates the involvement of GLUT1 in CCA development.

GLUT1 expression is associated with progressive phenotypes of CCA cell lines. Two CCA cell lines established from primary CCA tissues of two Thai patients in whom liver-

Figure 2. GLUT1 expression in the liver sections from the Ov-induced cholangiocarcinoma (CCA) hamster model. GLUT1 was highly expressed in the Ov + NDMA-induced CCA group, but not in the control groups (A). 200 $\times$ magnification; scale bar=100 μ m. The immunohistochemistry (IHC) scores from each histopathologic bile duct from all groups of animals were determined and compared (B). Number=number of bile ducts with positive GLUT1/total. NBD, normal bile duct; HP, hyperplasia; DP, dysplasia; M, month.

Figure 3. Expression of GLUT1 associated with aggressiveness of cholangiocarcinoma (CCA) cell lines. Two CCA cell lines, KKU-100 and KKU-213A, were treated with siGLUT1 for 48 h. Silencing of GLUT1 expression with siGLUT1 significantly decreased levels of GLUT1 mRNA (A) and GLUT1 protein (B) in CCA cell lines. Colony formation (C), migration (D) and invasion (E) of siGLUT1-treated cells were examined, compared to the scramble control cells (SC). MW, molecular weight, *** p <0.001.

fluke eggs were evident in tumor tissues of KKU-100 and KKU213A (15, 16), were used in this study. Silencing of GLUT1 expression using a specific siRNA towards GLUT1 (siGLUT1) was used to demonstrate the connection of GLUT1 with progressive phenotypes of CCA cell lines. Compared with the scramble control (SC) cells, CCA cells treated with siGLUT1 for 48 h effectively suppressed the expression of GLUT1 in both cell lines to 10-12% of RNA levels and 27-30% of protein levels (Figures 3A-B). The effect of GLUT1 on cells growth was investigated using a colony formation assay. Suppression of GLUT1 expression for 48 h significantly reduced the number of colony formations of KKU-100 to 44% and KKU-213A to 75% of the control cells ($p < 0.001$, Figure 3C).

The association of GLUT1 with migration and invasion abilities of CCA cells were next determined using Boyden chamber assays. Cells were treated with siGLUT1 for 48 h and harvested for the migration and invasion assays. siGLUT1 treatment significantly reduced the number of migrating cells of both cell lines to approximately 20-30% of SC cells ($p < 0.001$; Figure 3E). Similar results were observed for the invasion assay. Suppression of GLUT1 expression significantly inhibited invasion ability of both CCA cells to approximately 25% of the control cells ($p < 0.001$; Figure 3F).

Discussion

The expression of GLUT1 in association with progression of CCA has been previously demonstrated in non-fluke related CCA patients and cell lines (HuCCT1 and RBE cells) (12, 22). This study is the first to demonstrate the clinical relevance of GLUT1 expression in CCA tissues and its association with CCA development and an aggressive phenotype of CCA in liver fluke-related CCA. Knock-down of GLUT1 using GLUT1-siRNA suppressed the aggressiveness of CCA cells, suggesting GLUT1 as a potential therapeutic target for CCA.

The clinical relevance of GLUT1 and poor prognosis of CCA patients was emphasized in this study. High expression of GLUT1 was shown to be related with the aggressive non-papillary type CCA, large tumor size, and shorter survival of patients. Moreover, GLUT1 expression was an independent prognostic factor for CCA patients in this cohort. The association of GLUT1 expression with poor prognosis has been repeatedly reported in many cancer types including CCA (12, 22). This collective evidence indicated the involvement of GLUT1 in worse prognosis of CCA patients regardless of the etiology of the disease.

The gradual increasing of GLUT1-positive signals with the increasing degree of bile duct abnormality (hyperplasia, dysplasia and CCA) found in the hamster model, indicated the association of GLUT1 with CCA progression. This association was also observed in CCA tissues from patients. Positive GLUT1 signals were gradually detected in dysplastic lesions

and invasive CCA. In addition, high GLUT1 expression was found in the advanced non-papillary type and larger tumor sizes of CCA. The increasing expression of GLUT1 during progression of cancer may be an essential characteristic of cancer as this event was also observed in many types of cancer, such as cervical cancer (23), hepatoma (24), and oral tongue squamous cell carcinomas (25).

The association of GLUT1 with progression of CCA was demonstrated in two CCA cell lines, KKU-100 and KKU-213A. Silencing of GLUT1 expression using siGLUT1 significantly suppressed growth, migration and invasion of these cell lines. A similar observation has also been reported in non-fluke related CCA, *in vitro* and *in vivo* (12, 22). Specifically, Kubo *et al.* (12) demonstrated that suppression of GLUT1 using siRNA suppressed migration of CCA cells. In addition, Tiemin *et al.* showed that down-regulation of GLUT1 expression using shRNA or micro-RNA (miR-148a) specifically to GLUT1 could significantly reduce the aggressiveness of CCA cells *via* the reduction of cyclin D1 leading to G1 to S arrest and suppression of MMP2 expression (22). Moreover, suppression of GLUT1 could substantially sensitize CCA cells to gemcitabine *in vitro* and *in vivo* (22).

Increased aerobic glycolysis and glucose uptake in cancer cells has been attributed primarily to the up-regulation of GLUT1; hence, targeting GLUT1 as an anti-cancer strategy is well recognized (26). Liu *et al.* have demonstrated that treatment with WZB117, a synthetic small-molecule GLUT1 inhibitor, could reduce cancer cell growth, migration, and invasion of several cancer cell lines, *in vitro* and *in vivo* (26). Lung cancer cells treated with WZB117 had decreased intracellular ATP and glycolytic enzymes resulting in cell-cycle arrest and apoptosis (26). Additionally, it was shown that targeting GLUT1 as an anti-tumor therapy was more effective in inhibiting cancer cells than their non-cancerous cell counterparts and showed a synergistic effect when used in combination with cisplatin or paclitaxel (27).

Conclusion

High expression of GLUT1 was associated with carcinogenesis and progression of CCA, as well as with poor patient outcomes. Decreased GLUT1 expression using siGLUT1 significantly reduced aggressiveness of CCA cell lines, suggesting GLUT1 as a potential therapeutic target of CCA.

Conflicts of Interest

The Authors declare no conflicts of interest.

Authors' Contributions

UT performed the experiments, data analysis and drafted the manuscript. SS examined the immunohistochemistry and analysis. PS performed cell cultures. UC participated in the design of animal

study. SW and WS conceived the study and performed analysis and data interpretation. SW supervised the study and revised the manuscript. All authors participated in the interpretation of the studies and review of the manuscript.

Acknowledgements

This project was supported by the RGJ-PhD Program, TRF (PHD/0100/2560) to UT and SW; the co-funding of Khon Kaen University to RGJ (2561); the research grant from the Faculty of Medicine, (IN61328) and Cholangiocarcinoma Research Institute, Khon Kaen University to UT (CARI 01/2560). The authors would like to thank Prof. James A Will for editing this manuscript *via* the Faculty of Medicine Publication Clinic, KKU.

References

- Warburg O: On the origin of cancer cells. *Science* 123(3191): 309-314, 1956. PMID: 13298683. DOI: 10.1126/science.123.3191.309
- Kee HJ and Cheong JH: Tumor bioenergetics: An emerging avenue for cancer metabolism targeted therapy. *BMB Rep* 47(3): 158-166, 2014. PMID: 24499670. DOI: 10.5483/bmbrep.2014.47.3.273
- Thorens B and Mueckler M: Glucose transporters in the 21st century. *Am J Physiol Endocrinol Metab* 298(2): E141-145, 2010. PMID: 20009031. DOI: 10.1152/ajpendo.00712.2009
- Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajiaba MM, Begnami MD, Vilela RS, Paiva GR, Andrade RG and Soares FA: Glut1 expression in malignant tumors and its use as an immunodiagnostic marker. *Clinics (Sao Paulo)* 66(6): 965-972, 2011. PMID: 21808860. DOI: 10.1590/s1807-59322011000600008
- Zambrano A, Molt M, Uribe E and Salas M: Glut 1 in cancer cells and the inhibitory action of resveratrol as a potential therapeutic strategy. *Int J Mol Sci* 20(13), 2019. PMID: 31324056. DOI: 10.3390/ijms20133374
- Doki Y, Takachi K, Ishikawa O, Sasaki Y, Miyashiro I, Ohigashi H, Yano M, Ishihara R, Tsukamoto Y, Nishiyama K, Ishiguro S and Imaoka S: Reduced tumor vessel density and high expression of glucose transporter 1 suggest tumor hypoxia of squamous cell carcinoma of the esophagus surviving after radiotherapy. *Surgery* 137(5): 536-544, 2005. PMID: 15855926. DOI: 10.1016/j.surg.2005.01.008
- Kamsa-Ard S, Luvira V, Suwanrungruang K, Kamsa-Ard S, Luvira V, Santong C, Srisuk T, Pugkhem A, Bhudhisawasdi V and Pairojkul C: Cholangiocarcinoma trends, incidence, and relative survival in khon kaen, thailand from 1989 through 2013: A population-based cancer registry study. *J Epidemiol* 29(5): 197-204, 2019. PMID: 30078813. DOI: 10.2188/jea.JE20180007
- Sripa B, Kaewkes S, Sithithaworn P, Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana S, Thinkamrop B, Bethony JM, Loukas A and Brindley PJ: Liver fluke induces cholangiocarcinoma. *PLoS Med* 4(7): e201, 2007. PMID: 17622191. DOI: 10.1371/journal.pmed.0040201
- Komaya K, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Yamaguchi J and Nagino M: Recurrence after curative-intent resection of perihilar cholangiocarcinoma: Analysis of a large cohort with a close postoperative follow-up approach. *Surgery* 163(4): 732-738, 2018. PMID: 29336813. DOI: 10.1016/j.surg.2017.08.011
- Thamrongwarangoon U, Seubwai W, Phoomak C, Sangkhamanon S, Cha'on U, Boonmars T and Wongkham S: Targeting hexokinase ii as a possible therapy for cholangiocarcinoma. *Biochem Biophys Res Commun* 484(2): 409-415, 2017. PMID: 28131825. DOI: 10.1016/j.bbrc.2017.01.139
- Thonsri U, Seubwai W, Waraasawapati S, Sawanyawisuth K, Vaeteewoottacharn K, Boonmars T and Cha'on U: Overexpression of lactate dehydrogenase a in cholangiocarcinoma is correlated with poor prognosis. *Histol Histopathol* 32(5): 503-510, 2017. PMID: 27615379. DOI: 10.14670/HH-11-819
- Kubo Y, Aishima S, Tanaka Y, Shindo K, Mizuuchi Y, Abe K, Shirabe K, Maehara Y, Honda H and Oda Y: Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. *Hum Pathol* 45(8): 1610-1617, 2014. PMID: 24824030. DOI: 10.1016/j.humpath.2014.03.008
- Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PK, Chung AYY, Ooi L, Lim KH, Dima S, Duda DG, Popescu I, Broet P, Hsieh SY, Yu MC, Scarpa A, Lai J, Luo DX, Carvalho AL, Vettore AL, Rhee H, Park YN, Alexandrov LB, Gordan R, Rozen SG, Shibata T, Pairojkul C, Teh BT and Tan P: Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. *Cancer Discov* 7(10): 1116-1135, 2017. PMID: 28667006. DOI: 10.1158/2159-8290.CD-17-0368
- Indramanee S, Sawanyawisuth K, Silsirivanit A, Dana P, Phoomak C, Kariya R, Klinhom-On N, Sorin S, Wongkham C, Okada S and Wongkham S: Terminal fucose mediates progression of human cholangiocarcinoma through egf/egfr activation and the akt/erk signaling pathway. *Sci Rep* 9(1): 17266, 2019. PMID: 31754244. DOI: 10.1038/s41598-019-53601-8
- Sripa B, Leungwattananan S, Nitta T, Wongkham C, Bhudhisawasdi V, Puapairoj A, Sripa C and Miwa M: Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (kku-100). *World J Gastroenterol* 11(22): 3392-3397, 2005. PMID: 15948244. DOI: 10.3748/wjg.v11.i22.3392
- Sripa B, Seubwai W, Vaeteewoottacharn K, Sawanyawisuth K, Silsirivanit A, Kaewkong W, Muisuk K, Dana P, Phoomak C, Lert-Itthiporn W, Luvira V, Pairojkul C, Teh BT, Wongkham S, Okada S and Chamgramol Y: Functional and genetic characterization of three cell lines derived from a single tumor of an opisthorchis viverrini-associated cholangiocarcinoma patient. *Hum Cell* 33(3): 695-708, 2020. PMID: 32207095. DOI: 10.1007/s13577-020-00334-w
- Tang Z, Kang B, Li C, Chen T and Zhang Z: Gepia2: An enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res* 47(W1): W556-W560, 2019. PMID: 31114875. DOI: 10.1093/nar/gkz430
- Harlow E and Lane D: Preparing paraffin tissue sections for immunostaining. *CSH Protoc* 2006(1), 2006. PMID: 22485705. DOI: 10.1101/pdb.prot4329
- Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the folin phenol reagent. *J Biol Chem* 193(1): 265-275, 1951. PMID: 14907713.
- Bolt MW and Mahoney PA: High-efficiency blotting of proteins of diverse sizes following sodium dodecyl sulfate-polyacrylamide gel electrophoresis. *Anal Biochem* 247(2): 185-192, 1997. PMID: 9177676. DOI: 10.1006/abio.1997.2061

- 21 Zhang C, Liu J, Wu R, Liang Y, Lin M, Liu J, Chan CS, Hu W and Feng Z: Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target rad. *Oncotarget* 5(14): 5535-5546, 2014. PMID: 25114038. DOI: 10.18632/oncotarget.2137
- 22 Tiemin P, Peng X, Qingfu L, Yan W, Junlin X, Zhefeng H, Ming Z, Desen L and Qinghui M: Dysregulation of the mir-148a-glut1 axis promotes the progression and chemoresistance of human intrahepatic cholangiocarcinoma. *Oncogenesis* 9(2): 19, 2020. PMID: 32054829. DOI: 10.1038/s41389-020-0207-2
- 23 Mendez LE, Mancini N, Cantuaria G, Gomez-Marín O, Penalver M, Braunschweiler P and Nadji M: Expression of glucose transporter-1 in cervical cancer and its precursors. *Gynecol Oncol* 86(2): 138-143, 2002. PMID: 12144819. DOI: 10.1006/gyno.2002.6745
- 24 Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Scholmerich J, Oefner PJ, Kreutz M, Bosserhoff AK and Hellerbrand C: Glut1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. *Am J Pathol* 174(4): 1544-1552, 2009. PMID: 19286567. DOI: 10.2353/ajpath.2009.080596
- 25 Nakazato K, Mogushi K, Kayamori K, Tsuchiya M, Takahashi KI, Sumino J, Michi Y, Yoda T and Uzawa N: Glucose metabolism changes during the development and progression of oral tongue squamous cell carcinomas. *Oncol Lett* 18(2): 1372-1380, 2019. PMID: 31423200. DOI: 10.3892/ol.2019.10420
- 26 Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J and Chen X: A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth *in vitro* and *in vivo*. *Mol Cancer Ther* 11(8): 1672-1682, 2012. PMID: 22689530. DOI: 10.1158/1535-7163.MCT-12-0131
- 27 Li YL, Weng HC, Hsu JL, Lin SW, Guh JH and Hsu LC: The combination of mk-2206 and wzb117 exerts a synergistic cytotoxic effect against breast cancer cells. *Front Pharmacol* 10: 1311, 2019. PMID: 31780937. DOI: 10.3389/fphar.2019.01311

Received August 1, 2020

Revised October 9, 2020

Accepted October 12, 2020